🧪 ARA-290 10mg: Erythropoietin-Derived Peptide Research Profile
EPOR–CD131 Pathway Activation: ARA-290 acts as a selective agonist of the heteromeric erythropoietin receptor complex (EPOR–CD131), triggering downstream JAK2/STAT3 signaling involved in cellular repair and anti-inflammatory processes without stimulating erythropoiesis.
Neuropathy and Tissue Repair Models: Research on ARA-290 10mg focuses on its potential to modulate microvascular perfusion and promote neuronal recovery, making it valuable for studying peripheral nerve repair, neuropathic pain mitigation, and ischemia-induced tissue stress responses.
Immune Modulation and Cytokine Balance: Laboratory studies indicate that ARA-290 may downregulate pro-inflammatory cytokines such as TNF-α and IL-6 while increasing the expression of cytoprotective enzymes (e.g., HO-1), supporting investigations into chronic inflammation and autoimmunity mechanisms.
Metabolic and Endothelial Research: Through its effects on insulin sensitivity and endothelial nitric oxide synthase (eNOS) activation, ARA-290 serves as a model for exploring vascular homeostasis and metabolic dysfunction associated with diabetes-related complications.
✅ ARA-290 10mg Product Specifications
| Specification | Detail |
|---|---|
| Product Name | ARA-290 (Cibinetide) 10mg |
| Molecular Formula | C64H96N18O14 |
| Molecular Weight | 1330.56 g/mol |
| Concentration | 10 mg per vial |
| Sequence | Ala-Glu-Arg-Ala-Ala-Leu-Ser-Gln-Glu-Gly-Ala-Leu-Leu-Lys-Lys-Tyr-Leu-Leu-Gln-Gln (H–N terminus amidated) |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in sterile water or 1% acetic acid |
❄️ Product Care & Handling Guidelines
Unreconstituted (Powder): Store ARA-290 10mg in a dry, light-protected environment at -20°C to -80°C for long-term stability. Avoid exposure to high humidity or direct sunlight to prevent peptide oxidation.
Reconstituted (Liquid): For short-term storage, keep reconstituted solutions at 2°C to 8°C and use within 48 hours. For extended storage (up to 7 days), freeze at -20°C in aliquots and avoid repeated freeze–thaw cycles.
Handling Note: Like other short-chain peptides, ARA-290 may adsorb to plastic and glass at low concentrations. Researchers often use low-binding or siliconized vials and may add a carrier protein (e.g., 0.1% BSA) to minimize peptide loss.
📚 References & Resources
NCBI PubMed: https://pubmed.ncbi.nlm.nih.gov/23630364/ (Mechanisms of Action)
NCBI PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC4105270/ (Inflammatory and Neural Studies)
Frontiers in Pharmacology: https://www.frontiersin.org/articles/10.3389/fphar.2018.00690 (Endothelial Repair Research)
ScienceDirect: https://www.sciencedirect.com/science/article/pii/S2212958821000525 (Metabolic Regulation Studies)
⚠️ Laboratory Research Use Only Notice
The ARA-290 10mg product is strictly intended for in vitro and other non-clinical laboratory research purposes only. It is not approved for human consumption, medical, or veterinary use. The information provided is for scientific and educational reference only. None of the statements herein have been evaluated by the Food and Drug Administration (FDA).
